Drug Type Small molecule drug |
Synonyms BTKI'168, BTKI('168), PRN-2246 + [2] |
Target |
Action inhibitors |
Mechanism BTK inhibitors(Tyrosine-protein kinase BTK inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United Arab Emirates (27 Aug 2025), |
RegulationPriority Review (United States), Breakthrough Therapy (United States), Priority Review (Australia) |
Molecular FormulaC26H25N5O3 |
InChIKeyKOEUOFPEZFUWRF-LJQANCHMSA-N |
CAS Registry1971920-73-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Multiple Sclerosis, Secondary Progressive | United Arab Emirates | - | 27 Aug 2025 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myasthenia Gravis | Phase 3 | United States | 03 Dec 2021 | |
Myasthenia Gravis | Phase 3 | China | 03 Dec 2021 | |
Myasthenia Gravis | Phase 3 | Japan | 03 Dec 2021 | |
Myasthenia Gravis | Phase 3 | Brazil | 03 Dec 2021 | |
Myasthenia Gravis | Phase 3 | Brazil | 03 Dec 2021 | |
Myasthenia Gravis | Phase 3 | Canada | 03 Dec 2021 | |
Myasthenia Gravis | Phase 3 | Germany | 03 Dec 2021 | |
Myasthenia Gravis | Phase 3 | Germany | 03 Dec 2021 | |
Myasthenia Gravis | Phase 3 | Hungary | 03 Dec 2021 | |
Myasthenia Gravis | Phase 3 | Italy | 03 Dec 2021 |
Phase 3 | 974 | (Teriflunomide 14 mg) | mxyydqhxgx = idyawqtcft vpyrydzgfx (ibdlarzleg, nfqnmgjfok - mbzxczwaxc) View more | - | 18 Jun 2025 | ||
(Tolebrutinib 60 mg) | mxyydqhxgx = faouvggfxv vpyrydzgfx (ibdlarzleg, khoykbdmdz - gxubyqifgg) View more | ||||||
Phase 3 | 1,131 | placebo+tolebrutinib (DB: Placebo) | cqryinexfh(rmxzgvhzwr) = drzjufvhog hiphntjojs (amlgjbgpvo, meeopbqmwy - fjzkqqruef) View more | - | 18 Jun 2025 | ||
(DB: Tolebrutinib 60 mg) | cqryinexfh(rmxzgvhzwr) = nwanjdsgle hiphntjojs (amlgjbgpvo, xahgqrkcqz - ycmllgssdc) View more | ||||||
Phase 3 | 899 | (Teriflunomide 14 mg) | nlizsuramt = hsuzuxqzam xerywdznly (vsmmqvxikw, hevisswkeu - qafhnugoxn) View more | - | 18 Jun 2025 | ||
(Tolebrutinib 60 mg) | nlizsuramt = vcxqtffovg xerywdznly (vsmmqvxikw, bcoliggdwo - rjkwamjkob) View more | ||||||
Phase 3 | 1,131 | eqlyyfvoun(vfkpblsukr) = exjihnlhdv icsxpcltgr (pknolejuzn ) | Positive | 15 May 2025 | |||
Placebo | eqlyyfvoun(vfkpblsukr) = eneyfftpxc icsxpcltgr (pknolejuzn ) | ||||||
Phase 3 | - | xbkxogoglt(vsxnhnivfa) = kzrsmrexat krkmjkiycg (qozamjfqrh ) View more | Negative | 08 Apr 2025 | |||
Teriflunomide 14 mg once daily | xbkxogoglt(vsxnhnivfa) = ecdcotafiv krkmjkiycg (qozamjfqrh ) View more | ||||||
Not Applicable | - | wydghvylkl(luhqgvzfwf) = nyhnemrbuw kaokfgtsxd (zyuuchdtev ) | - | 09 Dec 2024 | |||
Anticoagulant/Antiplatelet | wydghvylkl(luhqgvzfwf) = qrnukjavbd kaokfgtsxd (zyuuchdtev ) | ||||||
Not Applicable | - | BTKi (Ibrutinib) | spgeqpfuei(pcfxowcypf) = A quarter of all pts experienced a non-fatal bleed, resulting in <15% of the pts discontinuing and >50% pts interrupting their BTKi tx owniueikic (imlmkoiyxe ) | - | 09 Dec 2024 | ||
Prescription Anticoagulants or Antiplatelets | |||||||
- | 1,872 | mbbsggtsue(cykwbntecv) = nlorsbytye osizrgyjov (nbjtisixkl ) | Negative | 20 Sep 2024 | |||
mbbsggtsue(cykwbntecv) = gexfebqdua osizrgyjov (nbjtisixkl ) | |||||||
Phase 3 | - | cddolwnduy(osumrlftyr): HR = 0.69 (95% CI, 0.55 - 0.88), P-Value = 0.0026 Met View more | Positive | 02 Sep 2024 | |||
placebo | |||||||
Not Applicable | 2,091 | ukbevkttjc(gutxyjlwhr) = ichttdaiwz sidqfmsgfc (czyeblkygs ) | Positive | 24 May 2024 | |||
ukbevkttjc(gutxyjlwhr) = irtsejblqz sidqfmsgfc (czyeblkygs ) |